Universe Pharmaceuticals (UPC) Common Equity (2020 - 2025)

Universe Pharmaceuticals (UPC) has 6 years of Common Equity data on file, last reported at $56.1 billion in Q3 2025.

• For the quarter ending Q3 2025, Common Equity rose 23.35% year-over-year to $56.1 billion; the trailing twelve-month figure through Sep 2025 stood at $56.1 billion (up 23.35% YoY), and the FY2025 full-year result was $56.1 billion, up 23.35% from the prior year.
• Common Equity advanced to $56.1 billion in Q3 2025, from $45.5 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $56.1 billion in Q3 2025 to a low of $26.7 million in Q1 2024.
• A 5-year average of $20.6 billion and a median of $14.0 billion in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 75083.64% in 2022 and plunged 43.25% in 2024, its largest moves.
• Tracing UPC's Common Equity over 5 years: stood at $47.0 million in 2021, then soared by 75083.64% to $35.3 billion in 2022, then retreated by 20.83% to $28.0 billion in 2023, then jumped by 62.68% to $45.5 billion in 2024, then gained by 23.35% to $56.1 billion in 2025.
• Business Quant data shows UPC's Common Equity at $56.1 billion in Q3 2025, $45.5 billion in Q3 2024, and $26.7 million in Q1 2024.